We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Metformin use in pregnancy: What about long‐term effects in offspring?
- Authors
Toft, Johanne Holm; Økland, Inger
- Abstract
Metformin use in pregnancy is increasing worldwide. Unlike insulin, metformin crosses the placenta. Consequently, maternal and fetal concentrations are comparable. Teratogenic effects are not reported, nor are adverse pregnancy outcomes. Reduced risk of hypertensive disorders, hypoglycemia, and macrosomia are potential benefits, together with lower gestational weight gain. Although metformin has been prescribed for pregnant women during the last 40 years, long‐term data regarding offspring outcomes are still lacking. Independent of maternal glycemic control, recent meta‐analyses report lower birthweight but accelerated postnatal growth and higher body mass index in metformin‐exposed children. The longest follow‐up study of placebo‐controlled metformin exposure in utero found an increased prevalence of central adiposity and obesity among children 5–10 years old. Recently, a Danish study reported a threefold increased risk of genital anomalies in boys, whose fathers used metformin around the time of conception. This commentary addresses the current controversies on metformin use in pregnancy.
- Subjects
METFORMIN; PREGNANCY outcomes; GLYCEMIC control; WEIGHT gain; BODY mass index
- Publication
Acta Obstetricia et Gynecologica Scandinavica, 2024, Vol 103, Issue 7, p1238
- ISSN
0001-6349
- Publication type
Article
- DOI
10.1111/aogs.14878